source
- Create Medicines raises $122M to bolster in vivo CAR-T therapiesThe fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.BioPharma Dive · 2mo ago↗ source
- Drugmakers have to go through rigorous tests to get a lower tariff rateLanding a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive or…Endpoints · 2mo ago↗ source
- Biogen pushing tau drug forward despite Alzheimer’s study failureOne of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of the biomarker and efficacy data” seen in a Phase 2 trial.